17 June 2025 - The Biosafety Advisory Council issues a positive advice (with conditions) for this deliberate release
File:
Trial reference:
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B